Phase 3 Study of the Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Renal Outcomes in Humans With Diabetic Kidney Disease

Trial Profile

Phase 3 Study of the Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Renal Outcomes in Humans With Diabetic Kidney Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2016

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Diabetic nephropathies; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 02 Mar 2016 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
    • 08 Jun 2015 Planned number of patients changed from 80 to 20 as per ClinicalTrials.gov record.
    • 08 Jun 2015 Planned primary completion date changed from 1 Nov 2016 to 1 Aug 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top